Literature DB >> 27105875

Can (68)GA-PSMA or radiolabeled choline PET/CT guide salvage lymph node dissection in recurrent prostate cancer?

Fabio Zattoni1,2, Andrea Guttilla3, Laura Evangelista4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27105875     DOI： 10.1007/s00259-016-3401-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  8 in total

1.  Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography.

Authors:  Patrizio Rigatti; Nazareno Suardi; Alberto Briganti; Luigi F Da Pozzo; Manuela Tutolo; Luca Villa; Andrea Gallina; Umberto Capitanio; Firas Abdollah; Vincenzo Scattoni; Renzo Colombo; Massimo Freschi; Maria Picchio; Cristina Messa; Giorgio Guazzoni; Francesco Montorsi
Journal:  Eur Urol       Date:  2011-08-03       Impact factor: 20.096

Review 2.  The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.

Authors:  Jonathan I Epstein; Lars Egevad; Mahul B Amin; Brett Delahunt; John R Srigley; Peter A Humphrey
Journal:  Am J Surg Pathol       Date:  2016-02       Impact factor: 6.394

3.  Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with (68)Ga-PSMA-HBED-CC than with (18)F-Fluoroethylcholine PET/CT.

Authors:  David Pfister; Daniel Porres; Axel Heidenreich; Isabel Heidegger; Ruth Knuechel; Florian Steib; Florian F Behrendt; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-19       Impact factor: 9.236

Review 4.  Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature.

Authors:  Piet Ost; Alberto Bossi; Karel Decaestecker; Gert De Meerleer; Gianluca Giannarini; R Jeffrey Karnes; Mack Roach; Alberto Briganti
Journal:  Eur Urol       Date:  2014-09-17       Impact factor: 20.096

5.  [11C]Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study.

Authors:  Ludwig Rinnab; Felix M Mottaghy; Joerg Simon; Bjoern G Volkmer; Robert de Petriconi; Richard E Hautmann; Markus Wittbrodt; Guenther Egghart; Peter Moeller; Norbert Blumstein; Sven Reske; Rainer Kuefer
Journal:  Urol Int       Date:  2008-08-29       Impact factor: 2.089

Review 6.  Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy.

Authors:  Firas Abdollah; Alberto Briganti; Francesco Montorsi; Arnulf Stenzl; Christian Stief; Bertrand Tombal; Hein Van Poppel; Karim Touijer
Journal:  Eur Urol       Date:  2014-03-26       Impact factor: 20.096

7.  Mid-term Outcomes Following Salvage Lymph Node Dissection for Prostate Cancer Nodal Recurrence Status Post-radical Prostatectomy.

Authors:  Fabio Zattoni; Avinash Nehra; Christopher R Murphy; Laureano Rangel; Lance Mynderse; Val Lowe; Eugene Kwon; R Jeffrey Karnes
Journal:  Eur Urol Focus       Date:  2016-02-10

8.  Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years.

Authors:  Nazareno Suardi; Giorgio Gandaglia; Andrea Gallina; Ettore Di Trapani; Vincenzo Scattoni; Damiano Vizziello; Vito Cucchiara; Roberto Bertini; Renzo Colombo; Maria Picchio; Giampiero Giovacchini; Francesco Montorsi; Alberto Briganti
Journal:  Eur Urol       Date:  2014-02-18       Impact factor: 20.096
  8 in total
  1 in total

Review 1.  PET imaging for lymph node dissection in prostate cancer.

Authors:  Elena Incerti; Paola Mapelli; Luigi Gianolli; Maria Picchio
Journal:  World J Urol       Date:  2016-10-17       Impact factor: 4.226
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.